Abstract：
Hepatocellular carcinoma (HCC) poses a heavy burden on human health with high morbidity and mortality rates. Systematic therapy is crucial for advanced and mid-term HCC, but faces a significant challenge from therapeutic resistance, weakening drug effectiveness. Metabolic reprogramming has gained attention as a key contributor to therapeutic resistance. Cells change their metabolism to meet energy demands, adapt to growth needs, or resist environmental pressures. Understanding key enzyme expression patterns and metabolic pathway interactions is vital to comprehend HCC occurrence, development, and treatment resistance. Exploring metabolic enzyme reprogramming and pathways is essential to identify breakthrough points for HCC treatment. Targeting metabolic enzymes with inhibitors is key to addressing these points. Inhibitors, combined with systemic therapeutic drugs, can alleviate resistance, prolong overall survival for advanced HCC, and offer mid-term HCC patients a chance for radical resection. Advances in metabolic research methods, from genomics to metabolomics and cells to organoids, help build the HCC metabolic reprogramming network. Recent progress in biomaterials and nanotechnology impacts drug targeting and effectiveness, providing new solutions for systemic therapeutic drug resistance. This review focuses on metabolic enzyme changes, pathway interactions, enzyme inhibitors, research methods, and drug delivery targeting metabolic reprogramming, offering valuable references for metabolic approaches to HCC treatment.
摘要：
肝细胞癌（HCC）对人类健康构成了沉重的负担，具有很高的发病率和死亡率。系统治疗对于晚期和中期HCC至关重要，但面临治疗抗性的重大挑战，削弱药物的有效性。代谢重编程作为治疗抗性的关键促成因素而受到关注。细胞改变新陈代谢来满足能量需求，适应成长需要,或抵抗环境压力。了解关键的酶表达模式和代谢途径相互作用对于理解HCC的发生至关重要。发展,和治疗阻力。探索代谢酶重编程和途径对于确定HCC治疗的突破口至关重要。用抑制剂靶向代谢酶是解决这些问题的关键。抑制剂,结合全身治疗药物，可以减轻抵抗力，延长晚期肝癌的总生存期，并为中期肝癌患者提供根治性切除的机会。代谢研究方法的进展，从基因组学到代谢组学，从细胞到类器官，帮助建立HCC代谢重编程网络。生物材料和纳米技术的最新进展影响药物靶向和有效性，为系统治疗性耐药提供新的解决方案。本文综述了代谢酶的变化,途径相互作用，酶抑制剂，研究方法,和靶向代谢重编程的药物递送，为肝癌的代谢治疗方法提供有价值的参考。
